Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) EPS (Weighted Average and Diluted) (2023 - 2025)

Perspective Therapeutics (CATX) has disclosed EPS (Weighted Average and Diluted) for 3 consecutive years, with -$0.52 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 14.75% to -$0.52 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.41 through Dec 2025, down 13.71% year-over-year, with the annual reading at -$1.41 for FY2025, 14.63% down from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.52 in Q4 2025 for Perspective Therapeutics, down from -$0.35 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.01 in Q1 2023 to a low of -$0.61 in Q4 2024.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.33 across 3 years, with a median of -$0.32 in 2025.
  • Biggest YoY gain for EPS (Weighted Average and Diluted) was 55.0% in 2024; the steepest drop was 3642.28% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.57 in 2023, then fell by 7.02% to -$0.61 in 2024, then rose by 14.75% to -$0.52 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for CATX at -$0.52 in Q4 2025, -$0.35 in Q3 2025, and -$0.29 in Q2 2025.